Investors interested in Oils-Energy stocks should always be looking to find the best-performing companies in the group. Has Continental Resources (CLR) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.Continental Resources is one of 251 companies in the Oils-Energy group. The Oils-Energy group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. CLR is currently sporting a Zacks Rank of #1 (Strong Buy).The Zacks Consensus Estimate for CLR's full-year earnings has moved 89.19% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.Based on the latest available data, CLR has gained about 101.17% so far this year. Meanwhile, the Oils-Energy sector has returned an average of 16.19% on a year-to-date basis. This means that Continental Resources is performing better than its sector in terms of year-to-date returns.To break things down more, CLR belongs to the Oil and Gas - Exploration and Production - United States industry, a group that includes 45 individual companies and currently sits at #14 in the Zacks Industry Rank. Stocks in this group have gained about 63.75% so far this year, so CLR is performing better this group in terms of year-to-date returns.Investors with an interest in Oils-Energy stocks should continue to track CLR. The stock will be looking to continue its solid performance. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Continental Resources, Inc. (CLR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research